Der Vaart Sandra D. Van Sells 1,314 Shares of Laboratory Co. of America Holdings (NYSE:LH) Stock

Laboratory Co. of America Holdings (NYSE:LH) EVP Der Vaart Sandra D. Van sold 1,314 shares of the stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $251.30, for a total value of $330,208.20. Following the transaction, the executive vice president now owns 2,171 shares of the company’s stock, valued at $545,572.30. This represents a 37.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Laboratory Co. of America Stock Performance

LH stock opened at $251.45 on Friday. The company has a quick ratio of 1.30, a current ratio of 1.44 and a debt-to-equity ratio of 0.67. The business’s fifty day simple moving average is $241.20 and its two-hundred day simple moving average is $232.64. Laboratory Co. of America Holdings has a twelve month low of $191.97 and a twelve month high of $258.59. The firm has a market cap of $21.03 billion, a price-to-earnings ratio of 28.51, a PEG ratio of 1.71 and a beta of 1.07.

Laboratory Co. of America (NYSE:LH) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $3.45 EPS for the quarter, beating the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. Analysts predict that Laboratory Co. of America Holdings will post 16.01 earnings per share for the current year.

Laboratory Co. of America Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 12th. Stockholders of record on Thursday, February 27th will be paid a dividend of $0.72 per share. The ex-dividend date is Thursday, February 27th. This represents a $2.88 annualized dividend and a dividend yield of 1.15%. Laboratory Co. of America’s dividend payout ratio is currently 32.65%.

Hedge Funds Weigh In On Laboratory Co. of America

Institutional investors have recently made changes to their positions in the company. Capital City Trust Co. FL increased its stake in shares of Laboratory Co. of America by 1.5% during the fourth quarter. Capital City Trust Co. FL now owns 15,553 shares of the medical research company’s stock valued at $3,567,000 after buying an additional 223 shares during the period. OneDigital Investment Advisors LLC increased its stake in shares of Laboratory Co. of America by 115.7% during the third quarter. OneDigital Investment Advisors LLC now owns 6,088 shares of the medical research company’s stock valued at $1,361,000 after buying an additional 3,265 shares during the period. Alexander Randolph Advisory Inc. purchased a new position in shares of Laboratory Co. of America during the third quarter valued at $955,000. Wealthcare Advisory Partners LLC increased its stake in shares of Laboratory Co. of America by 23.9% during the fourth quarter. Wealthcare Advisory Partners LLC now owns 2,543 shares of the medical research company’s stock valued at $583,000 after buying an additional 490 shares during the period. Finally, Mutual of America Capital Management LLC bought a new stake in Laboratory Co. of America during the third quarter valued at about $2,316,000. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. StockNews.com upgraded Laboratory Co. of America from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Morgan Stanley raised their price target on Laboratory Co. of America from $260.00 to $270.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 17th. UBS Group lowered their price target on Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Evercore ISI upgraded Laboratory Co. of America from an “in-line” rating to an “outperform” rating and raised their price target for the stock from $260.00 to $265.00 in a research report on Tuesday, January 7th. Finally, Bank of America raised their price target on Laboratory Co. of America from $262.00 to $271.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $265.75.

Laboratory Co. of America Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.